Jeremy M. Levin - Feb 20, 2025 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
CEO, Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
OVID
Transactions as of
Feb 20, 2025
Transactions value $
$0
Form type
4
Date filed
2/24/2025, 07:55 PM
Previous filing
Mar 20, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Employee Stock Option (Right to Buy) Award $0 +1.65M $0.00 1.65M Feb 20, 2025 Common Stock 1.65M $0.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date.